The CEO of Seattle Genetics, Inc., Clay Siegall, has an official blog where he likes to pass along news stories that are interesting. A recent article he linked to explored the reason that some immigrants are great in science. Many young people that are new to the US go into the STEM fields. The study broke down children who arrive in the US before and after age 10. As it turns out, the children that arrive after age 10 struggle with communication due to the language barrier. They turn to math and logic which makes them better at science, engineering, and the like.
Another article that Dr. Siegall posted looked at whether the EPA would reject a dangerous pesticide or its own scientific evidence. The EPA had decided to pull chlorpyrifos from the market as their research showed it is dangerous to consumers, however under the Trump Administration the EPA suddenly reversed course and is keeping it on the market. In the decision, it glossed over that the EPA had already determined that this pesticide is dangerous.
Clay Siegall, Ph.D., worked in biotechnology research & development for several years before he co-founded Seattle Genetics. Seattle Genetics is a company that develops cancer drugs using antibody-drug conjugates. The first cancer drug that reached FDA approval, Adcetris, was released in 2011 and is now used throughout the United States and Canada.
In addition to being CEO of Seattle Genetics, Dr. Siegall is also the Chairman of the Board. He is also a Director and board member for Ultragenyx Pharmaceutical which researches drugs for a number of rare and ultra-rare diseases.
Dr. Clay Siegall has won a number of awards during his career including in 2012 when he was awarded Entrepreneur of they Year by Ernst & Young. He was also named the University of Maryland Alumnus of the Year for Computer, Math, and Natural Sciences in 2013. Dr. Siegall earned his Bachelor’s Degree in Zoology from the University of Maryland. He attended George Washington University where he earned his Ph.D. in Genetics.